Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: paper man who wrote (331)	6/8/1998 6:55:00 PM
From: BARRY ALLEN	Read Replies (1) \| Respond to of 4891

Look at the facts paper man! A total of 43 patients with HIV-1 infection, who had never received anti-retroviral therapy, were randomized to receive either Reticulose (21 patients) or placebo (22 patients), at a dosage of two 1ml subcutaneous (SC) injections per day for two weeks, followed by 1ml SC per day every other week for a total of 60 days (total 30 days treatment). There were no toxic effects observed in, or reported by, patients receiving Reticulose. 12 out of 21 still ALIVE after 2 years with improved quality of life!! It was only administered to 21 patients originally! Damn good result! As good as AZT standing alone but without any side effects! I suggest you keep re-reading that article until it sinks in! Sorry.

To: paper man who wrote (331)	6/8/1998 6:56:00 PM
From: OLD JAKE JUSTUS	Respond to of 4891

In my humble opinion those results, if true, are indeed remarkable! Of course, I don't have the complete details. Therefore, I will refrain from making a final judgement, until all of the details are known. It looks very, very positive in my non-medical opinion. We have some doctors out there who may or may not agree with me on this subject. I wish I had their opinions here. But, they usually refrain from posting anywhere on SI. To me this is good news folks!

To: paper man who wrote (331)	6/8/1998 7:02:00 PM
From: sandbag	Read Replies (2) \| Respond to of 4891

Paper man Maybe I'm confused, but I don't think the article was very specific in terms of the study. It indicates that only 21 opted to stay on the treatment, but there were only 21 on the treatment to begin with (22 on a placebo). Of those 21, 12 are alive and continuing treatment, some (?) died who were in the advanced stages, and at least one 'was well enough to move on' (not the exact quote). I just think the article did not present the info properly and in the continuing studies, if patients are treated early enough and compared to a placebo group properly (by the media), I think we will see a totally different reaction. JMHO (for what it's worth) Sandbag

To: paper man who wrote (331)	6/8/1998 11:23:00 PM
From: BARRY ALLEN	Respond to of 4891

Sorry to harp on you, paper man, but did you ever hear of Merck's Crixivan? Well, shoot, it was only tested on 31 patients for 24 weeks and only 5 patients sustained the results for 1 year. Bullshit study, eh? We all know how successful MERCK is with Crixivan! How can you pooh-pooh ADVR's RETICULOSE study?? 2 YEARS and 12 of 21 patients alive and well!! Equal results compared to AZT!! In this trial, published in the New England Journal of Medicine (Gulick et al., NEJM 1997:337), of the patients who had previously received AZT, 90 percent of patients taking triple therapy with Crixivan, AZT and 3TC had virus levels below the level of detection at 24 weeks (28 out of 31 patients). This result was sustained for up to one year in the limited number of patients (5) who remained on blinded treatment in the study. The following adverse events have been noted for all protease inhibitors - new onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus and hyperglycemia. There have been reports of spontaneous bleeding in patients with hemophilia A and B. Crixivan has been approved in more than 80 countries. Merck has developed, with the American Dietetic Association, a list of foods, light meals or snacks that can be taken with Crixivan. Also, Merck recently announced the availability of additional information about Crixivan on Merck's new web site, www.crixivan.com. Merck's catalog price for Crixivan is $12 a day ($4,380 per year), or 22 to 36 percent lower than all other available protease inhibitors (Red Book, 1997).

To: paper man who wrote (331)	6/9/1998 12:06:00 AM
From: BARRY ALLEN	Respond to of 4891

Here's some more, paper man............old news. March 17, 1997 Protease Inhibitors Cleared For Children's Use by FDA By BRUCE INGERSOLL Staff Reporter of THE WALL STREET JOURNAL WASHINGTON -- The Food and Drug Administration gave children infected with the AIDS virus access to the same revolutionary drug therapy that has benefited so many adults. After raising $500 million from investors over its 13-year life, Agouron Pharmaceuticals is finally launching its first commercial product, a hot new biotechnology drug aimed against the virus that causes AIDS. Viracept, as an urgently needed drug, was put on the FDA's fast track and approved in just three months. The agency recommended using the drug in combination with other AIDS drugs.